anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
These study participants will be invited to attend a 60-90 minute educational seminar, entitled Destination: Transplant, delivered in a group setting. They will also receive monthly mailings for 9 months and a follow-up phone call from a transplant educator.
Participants aged less than (\<) 2 years old in dose escalation portion of the study will receive JNJ-75276617 orally on a 28-day cycle. Starting dose of JNJ-75276617 is based on the adult dose from the ongoing study NCT04811560 with additional dose reductions based on age. Further dose levels will be escalated based on the dose limiting toxicities (DLT) evaluation by study evaluation team (SET) until the recommended Phase 2 Doses (RP2Ds) has been identified. Participants in dose expansion portion of the study will receive JNJ-75276617 orally at one of the RP2D(s) determined in dose escalation portion of the study, in 3 cohorts divided on the basis of disease diagnosis. Participants with acute myeloid leukemia (AML) and B-cell acute lymphoblastic leukemia (ALL) will receive conventional chemotherapy backbone regimen (dexamethasone, vincristine, pegaspargase, fludarabine, cytarabine and intrathecal chemotherapy) in combination with JNJ-75276617.
BACKGROUND AND AIM: Intrathecal fentanyl, using the combined spinal-epidural (CSE) technique, provides rapid analgesia during early labour. Because of the technique's more complex and invasive nature, as its replacement we assessed the use of epidural analgesia in primiparous parturients with induced labour. The study was registered at www.
CLINICALTRIALS: gov (NCT04645823). The aim was to compare the efficacy, duration of analgesia and maternal satisfaction. The primary outcome was the difference in pain visual analogue scale (VAS) between the interventions at 20 min after the analgesia administration.
METHODS: Sixty volunteering parturients were randomly allocated in 1:1 ratio to receive either intrathecal fentanyl 20 μg or epidural analgesia (fentanyl 100 μg and lidocaine 80 mg). Contraction pain and maternal satisfaction were assessed by 0-100 mm VAS for 30 min, respectively. Foetal heart rate abnormalities, the time to first epidural dose and the incidence of pruritus were recorded. Non-inferiority margin for mean (95% CI) VAS after epidural analgesia was set at 20 mm above the VAS value for intrathecal fentanyl at 20 min.
RESULTS: The contraction pain VAS fell from (median [interquartile range, IQR]) 82 (14) to 13 (20) mm and 76 (17) to 12 (27) mm in 20 min following the intrathecal fentanyl and epidural analgesia, respectively. The absolute mean difference (epidural-intrathecal fentanyl) in the VAS values was 3.3(-0.06 to 6.66) mm indicating non-inferiority. The median time to reach VAS <30 mm was 10 min in both groups. The duration until request for supplemental analgesia was 82(69-95) and 91(75-106) min after intrathecal fentanyl and epidural analgesia, respectively. The difference for the duration (epidural-intrathecal fentanyl) was 9 (6-12) min and for satisfaction-VAS 0.3 (-3.0 to 3.7) mm. There were no differences between the groups in the incidence of foetal heart rate abnormalities, while pruritus was more common after intrathecal fentanyl.
CONCLUSION: After 20 min, epidural analgesia by lidocaine and fentanyl was within the non-inferior threshold compared with intrathecal fentanyl in efficacy. The duration of action was not shorter than that of intrathecal fentanyl and maternal satisfaction was also similar.
The present invention provides a method of preparing a vaccine. Said method includes: 1) analyzing specific antigen of particular pathogen; 2) obtaining a polynucleotide encoding the specific antigen; 3) obtaining a polynucleotide sequence having a sufficient difference from the polynucleotide; 4) preparing a vaccine using the polynucleotide sequence. The present invention also provides anti-tumor vaccines, particularly anti-tumor EGFR molecular vaccines.  Said anti-tumor EGFR molecular vaccines are a variety of new biotechnological vaccines constructed by using EGFR moleculars as anigens, including protein vaccines, gene vaccines, virus vaccines, gene-modified vaccines and stably transformed symbiotic bacterium. One of the biological function of the EGFR  molecular vaccines has an anti-tumor effect on a variety of solid tumor cancer which over-express the EGFR molecular, eg., lung cancer, breast cancer, ovary cancer, colon cancer, prostate cancer, stomach cancer, etc, including a protective anti-tumor immune effect, therapeutic anti-tumor effect and inhibiting cancer metastasis. The anti-tumor action mechanism of EGFR  molecular vaccine is that said EGFR moleculars may destroy an individual~s immune tolerance to self-EGFR molecular as cross-reactive antigens, and therefore induce an immuno-cross-response to the self-EGFR molecular in the individual, including active immune reaction (cellular immune reaction and humoral immune reaction) and passive immune reaction (adoptive immune reaction). Said anti-tumor EGFR molecular vaccines are either traditional preparation (aqua, lyophilized powder) or nano preparation prepared by nano biotechnology. Said EGFR molecular vaccine exhibits an enhanced anti-tumor effect through the synergistic action of other immunopotentiator.
Lumbosacral intervertebral disc herniation (IVDH) is a common cause of lower back pain in dogs and humans. In humans, the vertebral endplate to annulus fibrosus (AF) attachment was implicated as an alternative failure site besides rupture through the dorsal AF (AFF). Endplate junction failure (EPJF) is characterized by IVDH, accompanied by endplate irregularities (type A), rim avulsions (type B), or larger bony avulsions on one (type C) or both endplates (type D), associated with an adjacent endplate defect. This retrospective study reports the CT prevalence of presumed EPJF in dogs and its associations with signalment and other lumbosacral CT abnormalities. CT scans, including the lumbosacral spine of dogs obtained at two institutions, were assessed, yielding 324 scans. Presumed EPJF was found in 69 dogs (21%) and AFF in 68 dogs (21%), commonly at the caudal endplate of the last lumbar vertebra (71%). The remaining 187 dogs did not show presumed EPJF or AFF. Presumed EPJF type A occurred in 49/69, type B in 19/69, and type C in 1/69 dogs. Univariable logistic regression showed that presumed EPJF was associated with significantly higher IVDH grades than AFF. In the multiple regression model, presumed EPJF and AFF remained associated with increasing age and spondylosis deformans. Presumed EPJF was associated with vertebral endplate sclerosis and AFF with zygapophyseal joint osteoarthritis. In conclusion, presumed EPJF was observed on CT in 21% of dogs with lumbosacral IVDH. Prospective studies correlating EPJF on CT with clinical, surgical, and histopathological findings are needed for a better understanding of the underlying pathology and clinical relevance.
BACKGROUND: Cancer recurrence following surgical resection is a major cause of treatment failure. Finding effective methods to prevent postoperative recurrence and wound infection is an important component of successful surgery. With the development of new nanotechnology, more treatment options have been provided for postoperative adjuvant therapy. This study presents an innovative hydrogel system that stimulates tumoricidal immunity after surgical resection of non-small cell lung cancer (NSCLC) and prevents cancer relapse.
RESULTS: The hydrogel system is based on the excellent photothermal conversion performance of single-atom platinum (CN-Pt) along with the delivery and release of the chemotherapy drug, gemcitabine (GEM). The system is coated onto the wound surface after tumor removal with subsequent near-infrared (NIR) photothermal therapy, which efficiently induces necroptosis of residual cancer cells, amplifies the levels of damage-associated molecular patterns (DAMPs), and increases the number of M1 macrophages. The significantly higher levels of phagocytic macrophages enhance tumor immunogenicity and sensitize cancer cells to CD8 + T-cell immunity to control postoperative recurrence, which has been verified using an animal model of postoperative lung cancer recurrence. The CN-Pt-GEM-hydrogel with NIR can also inhibit postoperative wound infection.
CONCLUSIONS: These findings introduce an alternative strategy for supplementing antitumor immunity in patients undergoing resection of NSCLC tumors. The CN-Pt-GEM-hydrogel with the NIR system also exhibits good biosafety and may be adaptable for clinical application in relation to tumor resection surgery, wound tissue filling, infection prevention, and recurrence prevention.
The invention discloses an Ampelopsis cantoniensis-containing drug for preventing and treating hepatitis and belongs to the technical field of Chinese herbal medicine processing. The Ampelopsis cantoniensis-containing drug is prepared from Ampelopsis cantoniensis, stem or leaf of fortune euonymus, radix fici simplicissimae, root of Chinese Mahonia, stringy stonecrop herb, porcine bile, Artemisia sphaerocephala Kraschen seeds and an EM original liquid. Ampelopsis cantoniensis and stem or leaf of fortune euonymus as main raw materials have effects of clearing heat and toxins, disinhibiting dampness, diminishing swelling, promoting qi to activate blood, dispersing blood stasis and relieving pain, diminishing inflammation, easing pain, treating liver diseases and protecting liver. The radix fici simplicissimae has effects of invigorating spleen and tonifying lung, moving qi, relaxing tendons and activating collaterals, promoting qi-blood circulation to cure diseases. Stringy stonecrop herb and root of Chinese Mahonia have effects of clearing away heat and drying dampness, purging fire for removing toxins, diminishing swelling, and treating jaundice and acute and chronic hepatitis. The porcine bile can be easily absorbed and used by the human body and has special heat clearing and detoxifying icteric hepatitis treatment effects close to human pathological treatment effects. The Ampelopsis cantoniensis-containing drug has precise curative effects, is cheap, is prepared from easily accessible materials, is suitable for oral administration and external use and is conducive to disease prevention and treatment.
Participants in this group will have the following performed: Institute of Mobility Activity and Participation (I-MAP's) clinical battery of tests and a simulated driving test, a Brief Driving Behavior Interview, Propensity for Angry Driving Scale, Clinical Driving Assessment, Community Integration Questionnaire, and a Satisfaction with Life Questionnaire. Occupational Therapy Driving Intervention (OT-DI) consisting of three x 1 hour sessions to review explicit driving errors, strategies to mitigate errors, and driving simulator with feedback. The study will also obtain real world driving data from the Department of Motor Vehicles (public records) which includes citations, violations, and recorded collisions/crashes.
Digital weight loss interventions present a viable and cost-effective alternative to traditional therapy. However, further evidence is needed to establish the equal effectiveness of both approaches. This randomized controlled non-inferiority trial aimed to compare the effects of an intensive in-person weight loss intervention program with Vitadio digital therapy. One hundred patients with obesity and diagnosed with type 2 diabetes, prediabetes, or insulin resistance were enrolled and randomly assigned to one of the two treatment groups. Over a 6-month period, the control group received five in-person consultations with a physician who specialized in obesity treatment, a dietitian and/or a nutrition nurse, while the intervention group followed the digital program based on a multimodal therapeutic approach. The extent of weight loss was assessed and compared between the groups. Additionally, changes in body composition and metabolic parameters for the digital intervention group were analyzed. The study results demonstrated comparable effectiveness of both treatments for weight reduction. The positive effects of Vitadio were further evidenced by favorable changes in body composition and lipid metabolism and improved glycemic control in the intervention group. These findings suggest that Vitadio is an effective tool for assisting patients with managing obesity and preventing diabetes progression.
Oral Testosterone Therapy-396 mg given twice per day on days 1-7 and 15-21 of a 28 day cycle until radiographic progression. After a 21 day washout period, Enzalutamide therapy given at 160 mg once daily will be taken for a maximum of 6 cycles while on study.
Hypertensive renal disease (HRD) contributes to the progression of kidney dysfunction and ultimately leads to end-stage renal disease. Understanding the mechanisms underlying HRD is critical for the development of therapeutic strategies. Deubiquitinating enzymes (DUBs) have been recently highlighted in renal pathophysiology. In this study, we investigated the role of a DUB, OTU Domain-Containing Protein 1 (OTUD1), in HRD models. HRD was induced in wild-type or Otud1 knockout mice by chronic infusion of angiotensin II (Ang II, 1 μg/kg per min) through a micro-osmotic pump for 4 weeks. We found that OTUD1 expression levels were significantly elevated in the kidney tissues of Ang II-treated mice. Otud1 knockout significantly ameliorated Ang II-induced HRD, whereas OTUD1 overexpression exacerbated Ang II-induced kidney damage and fibrosis. Similar results were observed in TCMK-1 cells but not in SV40 MES-13 cells following Ang II (1 μM) treatment. In Ang II-challenged TCMK-1 cells, we demonstrated that OTUD1 bound to CDK9 and induced CDK9 deubiquitination: OTUD1 catalyzed K63 deubiquitination on CDK9 with its Cys320 playing a critical role, promoting CDK9 phosphorylation and activation to induce inflammatory responses and fibrosis in kidney epithelial cells. Administration of a CDK9 inhibitor NVP-2 significantly ameliorated Ang II-induced HRD in mice. This study demonstrates that OTUD1 mediates HRD by targeting CDK9 in kidney epithelial cells, suggesting OTUD1 is a potential target in treating this disease.
This stool will be 2 inches tall and be similar in appearance to the Squatty Potty. While sitting on the toilet, the subject supports her feet on the 2 inch high stool.
Damage-associated molecular patterns (DAMPs) such as extracellular ATP and nigericin (a bacterial toxin) not only act as potassium ion (K+) efflux inducers to activate NLRP3 inflammasome, leading to pyroptosis, but also induce cell death independently of NLRP3 expression. However, the roles of energy metabolism in determining NLRP3-dependent pyroptosis and -independent necrosis upon K+ efflux are incompletely understood. Here we established cellular models by pharmacological blockade of energy metabolism, followed by stimulation with a K+ efflux inducer (ATP or nigericin). Two energy metabolic inhibitors, namely CPI-613 that targets α-ketoglutarate dehydrogenase and pyruvate dehydrogenase (a rate-limiting enzyme) and 2-deoxy-d-glucose (2-DG) that targets hexokinase, are recruited in this study, and Nlrp3 gene knockout macrophages were used. Our data showed that CPI-613 and 2-DG dose-dependently inhibited NLRP3 inflammasome activation, but profoundly increased cell death in the presence of ATP or nigericin. The cell death was K+ efflux-induced but NLRP3-independent, which was associated with abrupt reactive oxygen species (ROS) production, reduction of mitochondrial membrane potential, and oligomerization of mitochondrial proteins, all indicating mitochondrial damage. Notably, the cell death induced by K+ efflux and blockade of energy metabolism was distinct from pyroptosis, apoptosis, necroptosis or ferroptosis. Furthermore, fructose 1,6-bisphosphate, a high-energy intermediate of glycolysis, significantly suppressed CPI-613+nigericin-induced mitochondrial damage and cell death. Collectively, our data show that energy deficiency diverts NLRP3 inflammasome activation-dependent pyroptosis to Nlrp3-independent necrosis upon K+ efflux inducers, which can be dampened by high-energy intermediate, highlighting a critical role of energy metabolism in cell survival and death under inflammatory conditions.
Patients with positive results in the fecal occult blood test in the Program for Early Detection of Colon and Rectal Cancer, undergone by the Consejeria de Salud de la Junta de Andalucia (Spain), were invited to participate in the CCR-microbiome study. This program is screening Andalusian population aged between 50 and 69 years old for colo-rectal cancer presence by fecal occult blood test, and further colonoscopy when positive for this test. Patients included in CCR-microbiome study were recruited between January 2017 and March 2020, at the Reina Sofia University Hospital (Cordoba, Spain) with the consumption of antibiotic within the previous month as exclusion criteria.
In this study, participants undergo threat conditioning to two pictures (CS+, CS-) in order to acquire a conditioned threat response. After this, the conditioned threat response is diminished through imaginal extinction (i.e extinction to the mental imagery of CS+ and CS-). Functional magnetic resonance imaging (7T) is used to measure neural activations during threat conditioning and imaginal extinction. Skin conductance is used to measure arousal response. Subjective fear and mental imagery vividness ratings will also be collected. In this way, this study aims to characterize the neural underpinnings of imaginal extinction.

Note that this study employs participants fearful of spiders. This is because data collection is shared with a related study (ClinicalTrials.gov ID 2020-06930a).
A pharmaceutical composition comprises an aqueous suspension of 4 : 41-diaminodiphenylsulphone in the presence of an intramuscularly-acceptable wetting agent and an intramuscularly acceptable suspending agent.  The wetting agents specified are non-ionic surface-active agents, e.g. the condensation products of ethylene oxide with an alkyl phenol, a long chain (i.e. C10-C18) fatty alcohol, a long chain (i.e. C10-C18) fatty acid or a long chain (i.e. C10-C18) fatty acid amide.  The examples use octyl cresol with 9 molecular parts of ethylene oxide.  The suspending agents are neutral hydrophilic colloids, e.g. sodium carboxy methyl cellulose, methyl cellulose, polyvinyl pyrollidone or a natural gum, e.g. tragacanth or an alginate.  The 4 : 41-diaminodiphenylsulphone, which should be present in the composition in the range of from 5 to 40 per cent by weight, is either dry ground, or wet ground using a dispersing agent, e.g. polyglyceryl ricinoleate to give a particle size of not greater than 100 microns.  Preservatives, e.g. chlorocresol, and a local anaesthetic, e.g. procaine may be incorporated in the composition.
The device will set on a tabletop in a room where the participant spends at least 2 hours in the morning. Using a timer, it will automatically turn on at preferred wakeup times (but no later than 09:00 am) chosen by the participant. Lights will remain on for at least 2 hours and participants will be asked to remain the space that lights are being applied for that period of time.
PURPOSE: A medical information managing network and a method thereof are provided to synthetically manage medical information by sending medical information about a medical service user by email. CONSTITUTION: A medical service user terminal(10) inputs medical information application agreement information of a medical service user. The medical service user terminal transmits the inputted information to a medical information integrated management system(30). The medical service user terminal stores an email account received from the medical information integrated management system. The medical service user terminal transmits information about the medical service user and the email account to a plurality of medical institution systems(20). [Reference numerals] (10) Medical service user terminal; (20) Medical institution system; (30) Medical information integrated management system; (31) Medical information DB; (32) Mail account generating unit; (33) Medical information receiving unit; (34) Medical information storage unit; (AA) Medical information transmitting unit; (BB) Information use agreement; (CC) Transmitting medical information
The research was planned as a descriptive study to be carried out in the general intensive care and emergency departments of the Sanatorium Hospital. After obtaining permission from the institution where the study will be conducted, the "Personal Information Form", "Attitude Towards Suicide Attempts" and "Stigma towards Suicide" scale will be sent to the nurses working in the general intensive care and emergency services of the hospital by the researcher online via Google Forms. Nurses, 5-10 min to answer. They will fill in the scales, which will continue, on their duty leave or on holidays.
This disclosure discloses a method and system for predicting disease quantification parameters for an anatomical structure. The method includes extracting a centerline structure based on a medical image. The method further includes predicting the disease quantification parameter for each sampling point on the extracted centerline structure by using a GNN, with each node corresponds to a sampling point on the extracted centerline structure and each edge corresponds to a spatial constraint relationship between the sampling points. For each node, a local feature is extracted based on the image patch for the corresponding sampling point by using a local feature encoder, and a global feature is extracted by using a global feature encoder based on a set of image patches for a set of sampling points, which include the corresponding sampling point and have a spatial constraint relationship defined by the centerline structure. Then, an embed feature is obtained based on both the local feature and the global feature and input into to the node. The method is able to integrate local and global consideration factors of the sampling points into the GNN to improve the prediction accuracy.
The recommended oral dose for the average patient (70 kg) is 3.7 to 14.8 MBq (100-400 µCi). The lower part of the dosage range 3.7 MBq (100 µCi) is recommended for uptake studies alone, and the higher part 14.8 MBq (400 µCi) for thyroid imaging. The determination of I 123 concentration in the thyroid gland may be initiated at six hours after administering the dose and should be measured in accordance with standardized procedures.

The patient dose should be measured by a suitable radioactive calibration system immediately prior to administration. The capsules can be utilized up to thirty (30) hours after calibration time and date. Thereafter, discard the capsules in accordance with standard safety procedures. The user should wear waterproof gloves at all times when handling the capsules or container.
This study was conducted to examine the effects of education on home accidents given to mothers of mentally disabled children aged 0-6. The sample of the study consisted of 83 mothers of mentally disabled children aged 0-6 registered in four special education centers in Kocaeli province between May 2023 and June 2024 (education group: 40 mothers; control group: 43 mothers). Research data were collected using the Information Form and the Scale for Diagnosing Mothers' Safety Precautions for Home Accidents in 0-6 Year Old Children. The mothers in the education and control groups were informed about the study, their written consent was obtained, and they were asked to fill out information forms. The mothers in the education group were given a single, 45-minute face-to-face education on preventing home accidents. The Mothers' Safety Measures for Home Accidents in Children aged 0-6 were administered the Scale before and one month after the training. The mothers in the control group did not receive any training; the Scale for Identifying Mothers' Safety Precautions for Home Accidents in Children Aged 0-6 was administered during the first interview and again one month later.